Elite in Multiple Myeloma

Mourad Tiab

Boulevard Stéphane Moreau, 
La Roche, FR 
Elite in Multiple Myeloma
Boulevard Stéphane Moreau, 
La Roche, FR 
OverviewLocationsClinical Research

Overview

Mourad Tiab practices in La Roche, France. Mr. Tiab is rated as an Elite expert by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Plasmacytoma, Prolymphocytic Leukemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 51 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 43 articles and participated in 4 clinical trials in the study of Multiple Myeloma.

Gender
Male

Locations

Boulevard Stéphane Moreau, La Roche, 85000, France
Other Locations
France
Limoges, France
Sours, France
Dunkerque, France
Nantes, France
Poitiers, France
La Roche, France
Bayonne, France
Amiens, France
Reims, France
Perigueux, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Enrollment Status: Completed
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Methotrexate, Cyclophosphamide
Study Phase: Phase 2
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Procedure, Drug
Study Drug: Pomalidomide+Cyclophosphamide+Dexamethasone
Study Phase: Phase 2
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Enrollment Status: Unknown
Publish Date: August 27, 2020
Intervention Type: Drug
Study Drug: Carfilzomib
Study Phase: Phase 2
View 5 Less Clinical Trials

51 Total Publications

Epistaxis and weight loss in a 73-year-old man
Epistaxis and weight loss in a 73-year-old man
Journal: La Revue de medecine interne
Published: April 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tiab's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile